Bio-Techne Corporation filed an 8-K press release on November 3, 2026, announcing a quarterly cash dividend of $0.08 per share for the quarter ended September 30, 2026, subject to a condition tied to its pending transaction with Merck KGaA, Darmstadt, Germany.

Key Highlights

  • Dividend amount: $0.08 per share for the quarter ended September 30, 2026, as declared by Bio-Techne's Board of Directors.
  • Payment date: November 23, 2026, to shareholders of record as of the close of business on November 13, 2026.
  • Conditional payment: The dividend will be paid only if Bio-Techne's pending transaction with Merck KGaA, Darmstadt, Germany has not closed on or before the close of business on November 13, 2026.
  • Future dividends: According to the filing, future cash dividends will be considered by the Board of Directors on a quarterly basis, as applicable.
  • Company scale: The filing states Bio-Techne generated over $1.2 billion in net sales in fiscal 2026 and has approximately 3,000 employees worldwide.

Bio-Techne's Conditional Quarterly Dividend and Pending Merck KGaA Transaction

Bio-Techne Corporation (NASDAQ:TECH), headquartered in Minneapolis, announced on November 3, 2026, that its Board of Directors declared a quarterly cash dividend of $0.08 per share for the quarter ended September 30, 2026. According to the filing, the dividend is payable on November 23, 2026, to common shareholders of record at the close of business on November 13, 2026.

The filing discloses a notable condition attached to this dividend payment: it will only be paid provided that Bio-Techne's previously announced transaction with Merck KGaA, Darmstadt, Germany has not closed on or before the close of business on the November 13, 2026 record date. The filing does not specify the financial terms of the pending transaction, but it identifies the deal as a factor that could affect whether shareholders receive this dividend.

The company described itself in the filing as "a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities," with products that "assist scientific investigations into biological processes and the nature and progress of specific diseases." The filing also notes that Bio-Techne generated over $1.2 billion in net sales in fiscal 2026 and employs approximately 3,000 people worldwide. The filing contains forward-looking statements, which the company identifies as subject to risks and uncertainties, including the timing of the pending transaction and whether required shareholder and regulatory approvals are obtained.

What Was Disclosed

Bio-Techne's Board declared a $0.08 per share quarterly dividend payable November 23, 2026, to shareholders of record on November 13, 2026, contingent on the pending Merck KGaA transaction not having closed by that record date.